Le Lézard
Classified in: Science and technology
Subjects: Product/Service, Funding, Business Update

Caduceus Capital Partners Names Executive Venture Partners for Second Investment Fund


Caduceus Capital Partners, LLC, a venture capital company focused on digital health investments, has named six executive venture partners who will play a key role in the firm's second fund, Caduceus Capital Partners Early-Stage Digital Health Fund II. These new executive venture partners include:

As active leaders in the investment process, these individuals will source and vet startups, hold director positions on portfolio company boards, support investment fund decisions and advise portfolio company executives.

Caduceus Capital Partners closed Fund I at $29 million in 2023, establishing it among the country's leading healthcare venture investment companies. Caduceus Capital Partners Early-Stage Digital Health Fund II plans to raise $50 million for investment in 15-20 companies over the next three to five years.

"We have achieved success and solid returns from our first Caduceus Capital Partners fund and are thrilled to launch Fund II with this team of incredible healthcare industry veterans," said Dave Vreeland, senior managing partner, Caduceus Capital Partners. "Our portfolio companies will benefit from their operational expertise, healthcare sales cycle guidance, market insights and extensive network of potential customers and partners."

Caduceus Capital Partners has established a distinctive model which focuses exclusively on digital health solutions to expand access, improve patient outcomes, reduce costs, further health equity and enhance the daily working lives of care providers. Caduceus Capital Partners Early-Stage Digital Health Fund II will center on investments in AI-enabled digital health.

"What sets Caduceus Capital Partners apart is our strategy of avoiding passive investments and inflated valuations. We nurture young digital health companies with sensible valuations, led by competent teams," said Scott Kolesar, managing partner, Caduceus Capital Partners. "With our model, we're able to make a real impact by securing significant ownership, participating in board memberships and providing extensive support to guide our portfolio companies to the next stage in their journeys."

About Caduceus Capital Partners, LLC

Caduceus Capital Partners invests in early-stage digital health companies that can make a significant impact on healthcare by expanding access, improving patient outcomes, reducing costs, furthering health equity and enhancing the daily working lives of care providers. The Caduceus Capital Partners investment model actively supports portfolio companies with operational expertise and network access to potential customers and partners. For more information and investment interest, visit www.caduceus.vc.


These press releases may also interest you

at 22:05
FPT Software signed a Memorandum of Understanding (MOU) with JAL Information Technology (JIT), a subsidiary of JAL Infotec - an aviation technology solutions and services provider under Japan Airlines. This partnership will see both sides...

at 22:00
Frost & Sullivan recently analyzed the hospital industry and noted that operational inefficiencies, workflow interruptions and shortage of skilled healthcare professionals are some key challenges faced by the healthcare industry. Based on its...

at 22:00
ICIS, a global source of commodity intelligence, has announced the 16th Asian Base Oils and Lubricants Conference will take place in Singapore, 27-28 June 2024. The event offers a platform for senior executives to connect with peers, potential...

at 21:00
Full Sail University's Annual Hall of Fame week kicked off with "Hall of Game." This esports event welcomed students and alumni to compete in popular titles including Call of Duty, Rocket League, and Super Smash Bros. Through Full Sail's partnership...

at 21:00
TIER IV, a pioneer in developing open-source software for autonomous driving (AD) systems, is set to launch a unique robotaxi service in November 2024. Initially targeting areas and times that conventional taxi operators struggle to serve, the...

at 20:14
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...



News published on and distributed by: